RxDoctor Payments Data

Steve Sitar, MD

Internal Medicine · Anaheim, CANPI 1700835360

Payments from drug & device makers

$1,536,438in general payments, 2019–2025

Across 276 payments — averaging $5566.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$821K
  • Incyte Corporation$233K
  • Sanofi US Services Inc.$150K
  • Lexicon Pharmaceuticals, Inc.$118K
  • Galderma Laboratories, L.p.$75K
  • Pfizer$49K
  • plus $90K from 15 others
$1,929in research payments, 2019–2025

Across 4 payments — averaging $482.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lexicon Pharmaceuticals, Inc.$2K
  • Eli Lilly$295

What the payments were for

  • Travel & lodging$1,17424%
  • Food & beverage$3,77576%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,536,438 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$13,987
Medicare patients
46
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$26,862
JanuviaSitagliptin Phosphate16$19,500
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,973
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$2,849
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$1,745
Atorvastatin Calcium153$1,675
Levothyroxine Sodium103$1,590
Albuterol Sulfate HfaAlbuterol Sulfate66$1,449
Losartan Potassium118$1,362
Amlodipine Besylate157$952
Wixela InhubFluticasone Propion/Salmeterol13$932
Metoprolol Succinate45$881
Labetalol Hcl12$872
Phenytoin Sodium Extended17$775
Duloxetine Hcl19$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48,986$26,86254 claims
MerckJanuvia$192$19,50016 claims
GSKAnoro Ellipta$122$5,97312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →